Last reviewed · How we verify
30% salicylic acid
At a glance
| Generic name | 30% salicylic acid |
|---|---|
| Also known as | Peeling agent |
| Sponsor | Combined Military Hospital Abbottabad |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Comparative Evaluation of the Role of Self-Adhesive Flowable Composite in Enhancing Sealant Retention Versus Conventional Pits and Fissure Sealant With and Without Fissurotomy in Permanent Molars (NA)
- Management of Bruxism in Patients With Implant Overdenture (PHASE1)
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (PHASE3)
- Clinical Performances of 3-different Tooth-colored Restorative Materials in Class-II Cavities (NA)
- Efficacy of Different Types of Chemical Peels in the Treatment of Acne Vulgaris (NA)
- Comparison of Bulk-Fill Composite Resins in Class II Restorations (NA)
- Autonomic Control of the Circulation and VDR (EARLY_PHASE1)
- Efficacy and Safety of 30% Salicylic Acid and 10% Nicotinamide Combined Therapy in Melasma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 30% salicylic acid CI brief — competitive landscape report
- 30% salicylic acid updates RSS · CI watch RSS
- Combined Military Hospital Abbottabad portfolio CI